To rigorously evaluate the clinical potential of repurposing L-NAME for the treatment of KRAS mutation-positive NSCLC, KrasLSL-G12D/+;Trp53LSL-R172H/+ mice were administered AdCre as above. Here, KRAS is linked to non-small cell lung carcinoma.